





EDUCATION BROCHURE



FEATURING OVER 230 HOURS OF EDUCATION, INCLUDING CUTTING-EDGE CLINICAL CONTENT DEVELOPED SPECIFICALLY FOR VISION EXPO

BROUGHT TO YOU BY



RX

PRODUCED BY

INTRODUCING NEW EDUCATION PRICING!*

We're thrilled to introduce new pricing which makes VisionEd more affordable than ever! Take advantage of hourly education, education for one day, or upgrade to unlimited education for the entire CE Program to take advantage of everything VisionEd has to offer!*

ALL EDUCATION REGISTRATIONS INCLUDE THE FOLLOWING:

- ADMISSION TO EXHIBITS (\$150 VALUE)
- ADMISSION TO EDUCATION ATTENDEE LOUNGE
- EDUCATION REGISTRATION PROCESSING FEE (\$50 VALUE)

*Unlimited education package does not include workshops.

DOCTORS

UNLIMITED CONTINUING EDUCATION

Regular: \$599

ONE DAY EDUCATION

Regular: \$409

A LA CARTE

\$70/hour

Select this option if you plan on taking fewer than 7 hours.

OPTICON / ALLIED HEALTH

Opticians, contact lens professionals, allied ophthalmic professionals, optical assistants and office managers, frame buyers and lab technicians.

OPTICON @ VISION EXPO UNLIMITED CONTINUING EDUCATION

Regular: \$299

OTHER PROFESSIONALS

PROFESSIONALS WORKING IN CORPORATE MANAGEMENT, OR SERVICE PROVIDERS

UNLIMITED CONTINUING EDUCATION

Regular: \$539

ONE DAY EDUCATION

Regular: \$389

A LA CARTE

\$70/hour

Select this option if you plan on taking fewer than 7 hours.

WORKSHOPS \$186

25L1: Scleral Lens Workshop **30C5:** OCT Workshop

*Unlimited education package does not include workshops.

FREE EDUCATION*

Global Contact Lens Forum: 10L1, 10L2, 10L3

March Madness Imaging Program: 10C1, 10C2, 10C3

(10C1 workshop limited to first 50 registrants)

Vision Series (Optometrists Only)

Innovation Stage


*Advance Registration is required for free courses.





2022 VISION EXPO **SUPPORTERS**













































2022 VISION EXPO ENDORSERS













SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM: BAUSCH & LOMB, J&J VISION, KALA, SIGHT SCIENCES, TARSUS

Official Institutional Sponsor:



EDUCATIONADVISORYBOARD

MEET THE MEMBERS WHO HAVE BEEN ACTIVELY INVOLVED IN THE DEVELOPMENT OF THIS YEAR'S EDUCATION MEETING.



Mark Dunbar, OD, FAAO, Co-Chairman CAB Chairman, Michigan College of Optometry at Ferris State University

Ben Gaddie, OD, FAAO,



Co-Chairman CAB Chairman, University of Alabama at Birmingham School of Optometry



Douglas Devries, OD Pacific University College of Optometry



Michael Kling, OD Southern College of Optometry



Thomas Quinn, OD Ohio University College of Medicine



Jack Schaeffer, OD University of Georgia, Southern College of Optometry



Kirk Smick, OD, FAAO Former CAB Chairman, Pacific University College of Optometry



Vincent Young, MD Temple University, Temple University **Medical School**

OPTICONADVISORYBOARD

MEET THE MEMBERS WHO HAVE BEEN ACTIVELY INVOLVED IN THE DEVELOPMENT OF THIS YEAR'S EDUCATION MEETING.



Janet Acara, ABOC, NCLEM **Erie Community College**



Tom Barracato, ABOC, NCLEC Owner, Adolph Optical



Sandra K. Brown, ABOM, NCLEC VisionWorks



Curt Duff, ABOM, NCLEM Owner, Tinder-Krauss-Tinder



David F. Meldrum, ABOM, NCLEC Mount Vernon Eye Care



OAB Co-Chair, Foerster & Hayes LTD, **ABO-NCLE Board Public Member**

Tina Palumbo



Carri L. Russell, NCLEM Bausch Health Speciality Vision Products **NCLE Chair**



Daniel M. Thomas, ABOC Eyes of the World



Phernell C. Walker, II, ABOM, NCLEC Pure Optics, LLC



Blair Wong, ABOM, NCLEC OAB Co-Chair, Benjamin Franklin Institute of Technology-Opticianry Department Chair

04 VISION EXPO EAST 2022

CLINICALHIGHLIGHTS

GLAUCOMA

- 11C1 The Glaucoma Suspect: Clinical Pearls for **Optimal Management**
- 13C1 Innovations in Glaucoma Drug Delivery: What the **Future Holds**
- 21C1 A Roadmap for Making the Diagnosis in Glaucoma
- 23C1 Treating the Newly Diagnosed Glaucoma Patient
- 24C1 New Medications in Glaucoma
- 25C1 A Roadmap for Identifying and Managing Progression in Glaucoma
- 26C1 A Roadmap for Medical Management of Glaucoma
- 30C4 MIGS in Glaucoma
- 30C5 OCT Workshop
- 31C1 The Secondary Glaucomas
- 33C1 Glaucoma Grand Rounds
- 34C1 Surgical Advances in Glaucoma Therapy

BLEPHARITIS

- 26C2 Anterior Segment Dilemmas
- 31C3 Demodex Principal, Conspirator, or Bystander in Dry Eye
- 32C2 The Greatest Anterior Seament Disease and Medical Management of Contact Lens Complications Course Ever
- 34C4 Don't Let Your Lids Get You Down

ANTERIOR SEGMENT

- 12C2 Biologics in the **Optometric Practice:** Lowering Inflammation With Amniotic Tissue
- 12C3 Going Viral: HZO, HSV. EKC
- 13C2 Are You Ready for Ocular Allergy Armageddon?
- 21C2 Pain Photophobia and Ocular Pathology: What You Should Know to Help Your Patient
- 22C2 Updates in Corneal Collagen Crosslinking
- 24C4 Treatment of Inflammatory Eyelid Disease with Photobiomodulation Therapy
- 25C2 MGD: New Technologies for Diagnosis and Management
- 30C7 Neurotrophic Cornea
- 31C2 Uveitis
- 33C2 Advances in Ocular Surface Disease: Treating Dry Eye
- 34C2 Digital Dry Eye
- 42C2 CSI: Anterior Segment Case Files
- 42C3 Red Eyes It's Just Conjunctivitis or Is It?

IMAGING TECHNOLOGY

- 10C1 March Madness: Case Challenges in Optometry - Optimizing Ocular Imaging Workshop
- 10C2 March Madness: Case Challenges in Optometry - Optimizing Ocular **Imaging Round 1**
- 10C3 March Madness: Case Challenges in Optometry - Optimizing Ocular Imaging Semifinals and Finals
- 22C3 OCTA
- 23C2 Visual Fields: A Virtual Reality
- 23C3 How OCT Forever **Changed Retina**
- 30C6 10 Hacks for OCT Interpretation in Glaucoma
- 31C5 OCT Connect: Maximizing Your OCT

SURGICAL/ **CO-MANAGEMENT**

- 22C4 Aesthetics in Optometry... a Therapeutic Approach:
- 23C6 Laser Therapy and **Advanced Procedures** Optometry
- 25C4 Rapidly Changing Landscape of Refractive Technology
- 33C4 20/20 Refractive Update: Advances in Presbyopic and Corneal Procedures
- 43C1 A New Era in Cataract and Refractive Surgical Management

HANDS ON WORKSHOP

25L1 Scleral Lens Workshop 30C5 OCT Workshop

CONTACT LENS

- Roadmap to Success in Contact Lens Practice
- Lessons Learned from **Favorite Contact Lens** Cases
- 10L3 Unconventional Marketing of Your Specialty Lens Practice
- 22L1 Scleral Lenses 101: **Basic Fitting**
- 23L1 Scleral Lens Advanced Fitting
- 24L1 Scleral Lens Troubleshooting
- 25L1 Scleral Lens Workshop
- 26L1 New and Innovative Uses for Contact Lenses
- 31L1 Tricks of the Trade with Torics
- 32L1 The Art and Science of Presbyopic CL Fitting
- Diagnosis and Treatment of the Irregular Cornea
- 42L1 Contact Lens Management of Keratoconus

LOW VISION

RETINA:

- 25C3 Today's Low Vision Made Easy
- 26C3 Low Vision Triage: The Gap Between Simple Magnification and Braille

21C5 The OD Role in Diabetes

Segment Disease

26C5 21st Century Retina Care

25C5 The Greatest Posterior

Course Ever

11C3 Oral Pharmaceuticals for **Anterior Segment** Disease

PHARMACOLOGY

- 25C6 Therapeutic Approaches to Presbyopia Management: The Dawn of a New Age
- 33C6 Top 10 Drugs: What's In Your Cabinet
- 34C6 Ocular Pain Management

POSTERIOR SEGMENT/ OPTOMETRIC/SURGICAL PROCEDURES

- Innovations in Glaucoma Drug Delivery: What the **Future Holds**
- Collagen Crosslinking
- Optometry...a Therapeutic Approach: IPL

22C2 Updates in Corneal

22C4 Aesthetics in

CLINICAL CONTENT

Custom designed for Vision Expo by the Education Advisory Board, our 2022 program is organized by key content areas including glaucoma, posterior segment/retina, anterior segment/dry eye, surgical/comanagement, and systemic disease and diabetes. Here you will discover courses specifically developed to immerse you in the most cutting-edge developments for better patient care. Learn from the most knowledgeable experts in the field of optometry as they unveil leading-edge technology and the latest trends in the diagnosis and treatment of common eye diseases. Nine clinical tracks with over 100 hours of content will keep you at the forefront of the industry.

VISION EXPO EAST 2022 REGISTER TODAY | VEE2022.COM/LEARN | #VISIONEXPO 07

EDUCATION HIGHLIGHTS

MYOPIA TRACK

Unlocking the Mystery of Myopia Management 7 Keys to Success

OWNER'S AND MANAGER'S ESSENTIALS PROGRAM

Reflecting today's biggest business challenges, this program for owners, managers and key decision makers will focus on the business side, including strategies to grow your business. Critical areas of focus include marketing your practice, growing and transitioning your practice, measuring financial success, building a great staff, competing in a digitally connected world, and building the ultimate optical business.

How To Become the Best Leader to Make Your Team Smarter 23B4 How I Built This: Building a New Practice from the Ground Up 33B3 Cold Start, Warm Start, Hot Start: Opening your first successful private practice in the world of private equity and consolidation 43B2 Creating Long Term Private Practice Success Through Real Estate

SCLERAL LENS TRACK

Scleral lens fitting is one of the fastest growing segments of specialty contact lens practice. Their impact can be profound and life changing both to the patient and the practice. This tract will provide comprehensive and highly clinical information on how to select a scleral lens design for both basic and advance cases, how to assess the fit and how to solve problems that may develop. Learn skills that will take your abilities and patient satisfaction to the next level.

22L1 Scleral Lenses 101: Basic Fitting Scleral Lenses: Advanced Fitting 24L1 Scleral Lens Troubleshooting 25L1 Scleral Lens Workshop

VISION SERIES

This all-new-for-2022 format invites you to grab a bite to eat or drink and continue learning over lunch. Take a break from the exhibit hall or formal classroom learning as industry leaders address the latest clinical innovations in a relaxed and collaborative learning environment. Then put theory into practice by heading back into the exhibit hall to connect and build on your classroom learning. Vision Series sessions are open to Optometrists only and are limited to one session per day. NOT FOR CREDIT.

Please check our website east.visionexpo.com for the list of Vision Series sessions.

INNOVATION STAGE

Located in The Bridge, the all-new Innovation Stage features free exhibitor-sponsored content for all attendees. Learn about the latest products and services over complimentary snacks and beverages in a casual, soft-seating environment.

Please check our website east.visionexpo.com for the list of Innovation Stage sessions.

FREE EDUCATION

GLOBAL CONTACT LENS FORUM

This free, informative and highly attended 'meeting within a meeting' provides attendees with practical, timely tips in both clinical and business processes that will take your specialty contact lens practice to the next level. A panel of respected, highly successful contact lens practitioners will provide personal insights gleaned from their road map to success. This will be followed by lessons learned from favorite contact lens cases. Finally, learn unconventional marketing of your specialty lens practice.

11:30AM-12:30PM

Marketing of Your

Speaker:

10L3 - Unconventional

THE GLOBAL CONTACT LENS FORUM IS DIRECTED BY THOMAS QUINN, OD

THURSDAY, MARCH 31

7:00 AM - 8:00 AM 10L1 - Roadmap to Success in Contact Lens SYMPOSIUM Practice

Moderator: Thomas Quinn, OD Panelists: Milton Hom. OD; Shalu Pal, OD; David Kading, OD

8:00 AM - 9:00 AM PROMOTIONAL BREAKFAST 10L2 - Lessons Learned A Contact Lens for **Every Patient** Speakers: Justin Kwan, OD, FAAO; Hom, OD; Shalu Pal, Jennifer Palombi, OD, OD; David Kading, OD

FAAO Presented by: Coopervision

NOT FOR CREDIT

9:15 AM - 11:15 AM from Favorite Contact Lens Cases **Speakers:** Thomas Quinn, OD; Milton

12:30PM-1:00PM PROMOTIONAL LUNCH SYMPOSIUM

Innovation Through **Specialty Lens Practice** Experience Speaker: Ben Gaddie, David Kading, OD OD FAAO Presented by:

> Bausch + Lomb NOT FOR CREDIT

1:00PM-1:30PM

Innovation: Myopia, Materials and Multifocal Speaker: Kurt Moody, OD, FAAO Presented by: Johnson & Johnson

NOT FOR CREDIT

4 HOURS FREE CE | ADVANCED REGISTRATION REQUIRED | ACCREDITATION PENDING - COPE, NCLE, FL BOARDS OF OPTOMETRY + OPTICIANRY, NY STATE OPTICIAN - CONTACT LENS - INTERMEDIATE

MARCH MADNESS

In the spirit of high stakes competition, panelists will compete against each other by presenting interesting cases highlighting imaging technology. The audience decides who wins each match via attendee interactive polling technology. The competition is fierce and the stakes are high as the loser goes home and the winner advances until the final showdown. Come be a part of this unique program that captures the thrill of victory and the agony of defeat as a champion gets crowned.

THURSDAY, MARCH 31

11:15AM-1:15PM 10C1 – March Madness: Case Challenges in Optometry - Optimizing Ocular **Imaging Workshop**

Speaker: Mark Dunbar, OD, FAAO

LIMITED ATTENDANCE

1:30PM-3:30PM 10C2 - March Madness: Case Challenges in Optometry -Optimizing Ocular Imaging Round 1

Moderator: Mark Dunbar, OD, FAAO Panelists: Julie Rodman, OD: Mohammad Rafieetary, OD: Steven Ferrucci, OD: Brad Sutton, OD; Carolyn Majcher, OD; Jay Haynie, OD; Joseph Pizzimenti, OD; Sherrol Reynolds, OD

3:45PM-4:45PM 10C3 - March Madness: Case Challenges in Optometry -**Optimizing Ocular Imaging** Semifinals and Finals

Moderator: Mark Dunbar, OD, FAAO Panelists: Julie Rodman, OD; Mohammad Rafieetary, OD; Steven Ferrucci, OD; Brad Sutton, OD; Carolyn Majcher, OD; Jay Haynie, OD; Joseph Pizzimenti, OD; Sherrol Reynolds, OD

5 HOURS FREE CE | ADVANCED REGISTRATION REQUIRED | ACCREDITATION PENDING - COPE, FL BOARD OF OPTOMETRY

THURSDAYMARCH31

FREE! GLOBAL CONTACT LENS FORUM

7:00 AM-	10L1 - FREE			
8:00 AM	Roadmap to Success in Contact Lens Practice			
	Moderator: Quinn Panelists: Hom, Pal, Kading	C,FL-OD, FL-OP,N-NO,NYS-CL-I		
9:15 AM -	10L2 - FREE			
11:15 AM	Lessons Learned from Favorite Contact Lens Cases			
	Quinn, Hom, Pal, Kading	C,FL-OD, FL-OP,N-O2,NYS-CL-I		
11:30 AM	10L3 - FREE			
-12:30 PM	Unconventional Marketing of Your Specialty Lens Practice			
	Kading	C,FL-OD, FL-OP,N-NO,NYS-CL-I		

			CLINICAL		
11:15AM					10C1 - FREE
-1:15PM					MARCH MADNESS Case Challenges in Optometry - Optimizing Ocular Imaging Workshop Speaker: Dunbar Limited Attendance
	11C1		11C3		C,FL-OD, N-NO 10C2 - FREE
1:30PM -3:30PM	The Glaucoma Suspect: Clinical Pearls for Optimal Management Chaglasian		Oral Pharmaceuticals for Anterior Segment Disease Lighthizer		MARCH MADNESS Case Challenges in Optometry - Optimizing Ocular Imaging Round 1 Moderator: Dunbar Panelists: Rodman, Ferrucci, Haynie, Rafieetary, Sutton, Majcher, Pizzimenti, Reynolds
	C,FL-OD,TPA,T		C,FL-OD,O,TPA,T		C,FL-OD, N-O2
3:45PM -		12C2	12C3	12C4	10C3 - FREE
4:45PM		Biologics in the Optometric Practice: Lowering Inflammation With	Going Viral: HZO, HSV, EKC Lighthizer	Modern Day Diabetes Gerson This course is 2 hours from 3:45pm-5:45pm	MARCH MADNESS Case Challenges in Optometry - Optimizing Ocular Imaging Semifinals and Finals
		Amniotic Tissue Devries			Moderator: Dunbar Panelists: Rodman, Ferrucci, Haynie, Rafieetary, Sutton, Majcher, Pizzimenti, Reynolds
			C, FL-OD, TPA, O		Moderator: Dunbar Panelists: Rodman, Ferrucci, Haynie, Rafieetary,
5:00PM	13C1	Devries	C, FL-OD, TPA, O		Moderator: Dunbar Panelists: Rodman, Ferrucci, Haynie, Rafieetary, Sutton, Majcher, Pizzimenti, Reynolds
5:00PM -6:00PM	I3C1 Innovations in Glaucoma Drug Delivery: What the Future Holds Schweitzer	Devries C,FL-OD	C, FL-OD, TPA, O		Moderator: Dunbar Panelists: Rodman, Ferrucci, Haynie, Rafieetary, Sutton, Majcher, Pizzimenti, Reynolds

TRACK KEY

Anterior Segment	Glaucoma	Imaging Technology	Myopia
Non-Track	Optometric/Surgical Procedures	Pharmacology	Posterior Segment/Retina
Scleral Lens	Surgical/Co-Management	Systemic Disease/Diabetes	



OPTICAL 1	TECHNOLOGY	BUS	INESS SOLUTIONS
1101	1102		11B2
Fundamentals for the Newer Optician Walker	Creating Patient Touchpoints Bob Alexander		Developing The CEO Within You Carlson
NYS-D-B,A-O2	A-O2, FL-T		C, FL-
1201			12B2
Night Vision Bob Alexander			The Art of Assortment Planning Martin
A-O3, FL-T, N-O3, NYS-D-I, NYS-CL-I			C, FL-
1301		13B1	13B2
Visual Perception: From Photon to Neuron Kotob		Creating Perceived Value Parker	Applying Retail Strategies in the Optical Dispensary Martin
FL-T,NYS-D/CL-I,A-O2		A-NO	C, FL-

ACCREDITATION LEGEND

A-NO/O1/O2/O3 – ABO-Non-Ophthalmic I/Ophthalmic II/Ophthalmic III, C – COPE, FL-OD – Florida State Board of Optometry, FL-OP – Florida State Board of Opticianry, FL-T – Florida State Board of Opticianry – Technical, N-NO/O1/O2/O3 – NCLE-Non-Ophthalmic I/Ophthalmic II/Ophthalmic III, NYS-D/CL – B/I/A – New York State Optician – Dispensing/Contact Lens – Basic/Intermediate/Advanced, O – Orals, P – AOA Paraoptometric Commission, T – TQ/CEE, TPA – Therapeutic



Provide your staff with the highest quality and most affordable opportunity to learn with a comprehensive package that includes unlimited hours of Education.

LOOK FOR THE OPTICON LOGO IN THE DAILY COURSE GRID SCHEDULE SIGNIFYING SESSIONS BEING DEVELOPED BY OPTICON.

10 VISION EXPO EAST 2022

FRIDAYAPRIL1

			CLINICAL				CONTACT LENS
7:15AM -	21C1	21C2			21C5		
8:15AM	A Roadmap for Making the Diagnosis in Glaucoma Chaglasian, Schmidt This course is 2 hours from 7:15am - 9:15am	Pain Photophobia and Ocular Pathology: What You Should Know to Help Your Patient Hom			The OD Role in Diabetes Reynolds This course is 2 hours from 7:15am - 9:15am		
		C,FL-OD,O,TPA					
8:30AM -		22C2	22C3	22C4		21C6	22L1
9:30AM		Updates in Corneal Collagen Crosslinking Gelles	OCTA Lighthizer	Aesthetics in Optometrya Therapeutic Approach: IPL McGee, Devries This course is 2 hours from 8:30am - 10:30am		Life Threatening Causes of Diplopia Marrelli	Scleral Lenses 101: Basic Fitting Barnett, Pal
	C EL-OD	C EL-OD	C FL-OD		C FI-OD	C EL-OD	C EL-OD
0.45414	C,FL-OD 23C1	C,FL-OD 23C2	C,FL-OD 23C3		C, FL-OD 23C5	C,FL-OD 23C6	C,FL-OD 23L1
9:45AM – 10:45AM	Treating the Newly Diagnosed Glaucoma Patient Gaddie	Visual Fields: A Virtual Reality Whitley	How OCT Forever Changed Retina Pizzimenti, Pelino This course is 2 hours from 9:45am – 11:45am		AMD Current Science and Trends in Diagnosis and Treatment Gerson, Rodman This course is 2 hours from 9:45am - 11:45am	Laser Therapy and Advanced Procedures Optometry Lighthizer	Scleral Lens Advanced Fitting Barnett, Pal
	C,FL-OD,TPA 24C1	C,FL-OD 24C2		C,FL-OD,TPA 24C4		C,FL-OD	C,FL-OD 24L1
11:00AM - 12:00PM	New Medications in Glaucoma Gaddie	Cultural Competence The Opportunities of Serving the Needs of Hispanic Patients Santiago		Treatment of Inflammatory Eyelid Disease with Photobiomodulation Therapy Hornberger			Scleral Lens Troubleshooting Barnett, Pal
	C, FL-OD,TPA	C, FL-OD	C,FL-OD	C,FL-OD	C, FL-OD		C,FL-OD,N-O3
12:15PM -	20C1	20C2	-	-	-		
1:15PM	Vision Series - Presented by Novartis - Myth Busters: Dry Eye Disease Hauser, Mattheis FREE, NOT FOR CREDIT. OPTOMETRISTS ONLY.	Vision Series - Presented by Bausch + Lomb - Practical Pearls, Innovative Products Gaddie, Tsai, Womack FREE, NOT FOR CREDIT. OPTOMETRISTS ONLY.					
2:45PM -	25C1	25C2	25C3	25C4	25C5	25C6	25L1
4:45PM	A Roadmap for Identifying and Managing Progression in Glaucoma Chaglasian, Fingeret	MGD: New Technologies for Diagnosis and Management M. Schaeffer, Hom, Devries	Today's Low Vision Made Easy Gannon, Porter, Gartner	Rapidly Changing Landscape of Refractive Technology Gelles	The Greatest Posterior Segment Disease Course Ever Haynie, Sutton, Dunbar	Therapeutic Approaches to Presbyopia Management: The Dawn of a New Age McGee	Scleral Lens Workshop Barnett, Pal, Kading Limited Attendance \$186
	C,FL-OD	C,FL-OD	C,FL-OD	C, FL-OD	C,FL-OD,T	C, FL-OD, TPA	C,FL-OD,N-O3
5:00PM -	26C1	26C2	26C3	26B4	26C5	26C6	26L1
6:00PM	A Roadmap for Medical Management of Glaucoma Schmidt	Neuro Ophthalmic Grand Rounds Pelino	Low Vision Triage: The Gap Between Simple Magnification and Braille Gannon	Developing A Game Plan for Headaches and Concussion Protocol Nanasy	21st Century Retina Care Majcher	Preparing Your Practice for Presbyopia J. Schaeffer, M. Schaeffer	New and Innovative Uses for Contact Lenses Kading
	C,FL-OD,TPA	C, FL-OD	C,FL-OD	C,FL-OD	C, FL-OD	C, FL-OD	C,FL-OD,N-O3

TRACK KEY

Anterior Segment	Glaucoma	Imaging Technology	Myopia
Non-Track	Optometric/Surgical Procedures	Pharmacology	Posterior Segment/Retina
Scleral Lens	Surgical/Co-Management	Systemic Disease/Diabetes	

ОРТ	ICAL TECHNO	LOGY		BUSINESS S	SOLUTIONS		
				21B2			
				How To Become the Best Leader to Make Your Team Smarter Johnston			
				C,FL-OD			
2201			22B1		22B3	22B4	22B5
Creating An Indispensable Impression Tami Hagemeyer			MBA Strategies to Maximizing Inventory ROI Walker		The Elderly Dispensing Tips to Practice By O'Keefe	How To Not Sell in the Exam Room Steele	Five Intelligence Strategies for a Successful Optical in Today's Climate (COVID-19 and Beyond) Gould
A-NO			A-O2		FL-OP,A-O2,N-O2, NYS-D/CL-B	C,FL-OD	C,FL-OD
2301	23O2	23O3			23B3	23B4	23B5
Designing and Crafting Strong and Unusual Lenses Dennis	Fundamentals of Progressive Lens Design Goffinet	Enhance Your Communication Skills Tami Hagemeyer			Branded Eyewear – What's The Big Deal? O'Keefe	How I Built This: Building a New Practice from the Ground Up Steele	Lost Revenue Opportunities and How To Reclaim Them Binkowitz
A-O2,FL-T,NYS-D-A	FL-T,NYS-D-I,A-O2	A-NO			A-NO	C,FL-OD	C,FL-OD
2401	2402		J.	24B1	24B3	24B4	24B5
J.O.B.S: Joint Opportunity to Believe in Staying Robin Brush	Soft Lens Fitting Spherical and Toric Gzik			Myopia Parker	A Positive Approach to Patient Objections O'Keefe	The 2022 Optometry Practice Re-Boot (COVD19 and Beyond) Gould	Building a Glaucoma Practice: Combing Standards of Care with Billing and Coding Klute
A-NO, FL-OP, NYS-D-I	FL-T,NYS-CL-I,N-O2			A-O2,FL-OP	A-01,N-01	C,FL-OD	C,FL-OD
OptiCon @ Vision Expo East 2022 General Session: Opticianry Leading the Way James Morris, Curt Duff, Justin Morris A-O1, N-O1							
2501	25O2		25B1	25B2		25B4	25B5
Working With	Biomicroscope Usage in a Contact Lens		The O'Keefe Sisters Top Dispensing Tips Pierce, O'Keefe,	Mega-brand SWAT; Strategy With Advanced Techniques		Great Team = Great Business Carlson	Building Your Business For Profit Binkowitz, Kling
Customized and Personalized Free- Form Lenses Dennis	Practice and Workshop Gzik S		O'Keefe-Culp	Walker		Carison	binkowiiz, kiing
Personalized Free- Form Lenses Dennis A-O1,FL-T,NYS-D-I	Gzik FL-T,NYS-CL-B,N-O3, A-O3		O'Keefe-Culp			C,FL-OD	C,FL-OD
Personalized Free- Form Lenses Dennis	Gzik FL-T,NYS-CL-B,N-O3,		O'Keefe-Culp	3	26B3		-
Personalized Free- Form Lenses Dennis A-O1,FL-T,NYS-D-I	Gzik FL-T,NYS-CL-B,N-O3, A-O3		O'Keefe-Culp	3	26B3 Building Sales Without Selling Binkowitz	C,FL-OD	-

ACCREDITATION IS PENDING

The "pending CE approval" courses are being submitted to the accrediting agencies for consideration of approval – if the accreditation designation is NOT listed, the course is NOT being submitted to that agency.

12 VISION EXPO EAST 2022

SATURDAYAPRIL2

	CONTACT LENS						
8:30AM -	31C1	31C2	31C3	31C4	31C5		31L1
9:30AM	The Secondary Glaucomas Marrelli This course is 2 hours from 8:30am - 10:30am	Uveitis M. Schaeffer, Schmidt C,FL-OD,O,TPA	Demodex Principal, Conspirator, or Bystander in Dry Eye Hom	Disruptive Technologies Thimons This course is 2 hours from 8:30am - 10:30am	OCT Connect: Maximizing Your OCT Rodman This course is 2 hours from 8:30am - 10:30am		Tricks of the Trade with Torics Pal C, FL-OD, N-O2
9:45AM -		32C2				32C6	32L1
10:45AM	C, FL-OD	The Greatest Anterior Segment Disease and Medical Management of Contact Lens Complications Course Ever Bloomenstein, Periman, J. Schaeffer		C,FL-OD	C,FL-OD	Unlocking the Mystery of Myopia Management 7 Keys to Success Kading This course is 2 hours from 9:45am - 11:45am	The Art and Science of Presbyopic CL Fitting Bennett, Quinn This course is 2 hours from 9:45am - 11:45am
11:00AM	30C4	This course is 2 hours from 9:45am – 11:45am	30C3	30C7	30C6		
-12:00PM	MIGS in Glaucoma Schweitzer, Whitley	y:45am - 11:45am	Optometry Meets Neurology, The link between Headaches and Dry Eye Sensation Corbin-Simon	Neurotrophic Cornea Koetting	10 Hacks for OCT Interpretation in Glaucoma Dunbar		
	C, FL-OD, TPA	C,FL-OD,O,TPA,T	C,FL-OD	C, FL-OD, TPA	C,FL-OD	C,FL-OD	C.FL-OD.N-O2
	30C1	30C2	30C5	5,1252,111	5, 2 2 2	4,	5, 2 2 2, 11 2 2
12:15PM – 2:30PM	Vision Series - Presented by Regeneron - Establishing a Partnership in the Effective Management of Patients with DR and DME Dunbar, Almeida This session is from 12:15pm-1:15pm	Vision Series - Presented by Zeiss - Glaucoma Management: The Value of Enhancing the Patient Experience Moderator: Chaglasian Panelists: Gould, Marrelli, Panarelli This session is from 12:15pm- 1:15pm	OCT Workshop Pizzimenti, Haynie This workshop is 2 hours from 12:30pm – 2:30pm				
	FREE, NOT FOR CREDIT. OPTOMETRISTS ONLY.	FREE, NOT FOR CREDIT. OPTOMETRISTS ONLY.	C.FL-OD				
2:45PM -	33C1	33C2		33C4		33C6	33L1
4:45PM	Glaucoma Grand Rounds Fingeret, Schmidt	Advances in Ocular Surface Disease: Treating Dry Eye Periman, J. Schaeffer, Bloomenstein		20/20 Refractive Update: Advances in Presbyopic and Corneal Procedures Johnston, Whitley		Top 10 Drugs: What's In Your Cabinet Thimons	Diagnosis and Treatment of the Irregular Cornea Quinn, Barnett
	C,FL-OD,TPA	C,FL-OD,TPA		C,FL-OD		C, FL-OD, O,TPA	C,FL-OD
5:00PM -	34C1	34C2		34C4		34C6	
6:00PM	Surgical Advances in Glaucoma Therapy Schweitzer	Digital Dry Eye Hom		Don't Let Your Lids Get You Down McGee		Ocular Pain Management Whitley	
	C,FL-OD,TPA	C, FL-OD, TPA		C, FL-OD, TPA		C,FL-OD,O,TPA	

TRACK KEY

Anterior Segment	Glaucoma	Imaging Technology	Myopia
Non-Track	Optometric/Surgical Procedures	Pharmacology	Posterior Segment/Retina
Scleral Lens	Surgical/Co-Management	Systemic Disease/Diabetes	

ALLIED HEALTH		OPTICAL TEC	HNOLOGY		BUSINE	SS SOLUT	TIONS
31A1	3101	3102	3103			31B3	31B4
The Medical Bases for Optical Prescription Changes Zeitlin	What's New in Wearable Technology Eyewear? Underwood	Fitting Beyond the Limbus Buckner	It's Not About You - What About the Patient? Robin Brush			The 8 Steps To A 5-Star Experience Gould	8 Common Cash Flow Pitfalls Kling
P	FL-T,NYS-D-I, A-O2	A, FL-T	A-NO, N-NO			C,FL-OD	C,FL-OD
32A1	3201	32O2	3203	3204	32B1	32B2	32B3
Allied Health Personnel's Role in Management of Ocular Emergencies Young This course is 2 hours from 9:45cm - 11:45cm	An Optician's Guide to Visual Impairment Underwood This course is 2 hours from 9.45am - 11:45am	Advancements in Photochromic Technology: Solutions for Today's World O'Keefe	Gas Permeable Fluorescein Patterns: Application & Removal Workshop Buckner This course is 2 hours from 9:45am - 11:45am	What the Patient Says vs. What the Patient Means Shana Zeitlin	MBA Strategies to Managing Your Practice and Optical Walker This course is 2 hours from 9:45am - 11:45am	Follow the Science: Clinical Decision- Making Using Evidence- Based Medicine Klute This course is 2 hours from 9:45am - 11:45am	Profit First: Eradicating Business Poverty Kling This course is 2 hours from 9:45am – 11:45am
_	FL-OP,NYS-D/CL-I,						
P	A-O2,N-O2 30O1		N, FL-T, NYS-CL-I	ABO PENDING	A-NO	C,FL-OD	C,FL-OD
	Moderator: Parker This session is from 12:30pm-1:30pm						
33A1	3301	33O2	33O3		33B1	33B2	33B3
Clinical Ocular Concepts for Opticians and Technicians Young	How to Get the Most Out of Your Digital Measuring Devices Underwood	Scleral Lens Fitting and Troubleshooting Buddy Russell	Soft Lens Fitting/ Application & Removal Workshop C. Russell		Management; Do You Have the Right Stuff? Walker	Choose the Right Code: Documentation Guidelines for Office Visits Klute	The Art of Starting Cold: From Private Equity, to COVID, and Beyond Baas, Steinmetz
P, A-O1	FL-T,NYS-D-I, A-O2	N-O3, FL-T, NYS-CL-I	N, FL-T, NYS-CL-I		A-NO, N-NO	C, FL-OD	C,FL-OD
34A1	3401	3402	3403		34B2	34B3	34B4
Cataract Surgery Comanagement for Opticians - Optical Solutions to Suboptimal Outcomes Zeitlin, Young	Advanced Ophthalmic Optics Walker	Compensated Powers (and Other Ophthalmic Conundrums) Parker	Fashion Optical Dispensing Manso		Connecting the Refraction with the Patient's Prescriptions Pierce	Private Practice Horror Stories Helmus	Key Performance Indicators that Drive Revenue and Optimize Your Cash Flow Gould
					FL-T,NYS-D/CL-I,		

ABOUT ACCREDITATION

The accreditation designations serve as a guide to assist you with course selections. The courses listed are "pending CE approval." Please refer to VEE2022.com/Policies for current CE approvals. You can change a course selection after you register by calling Client Services at 1.800.811.7151.

Vision Expo is not responsible for courses that do not receive accreditation. Do not assume that the courses you register for will be approved. You will not receive credit if you are late to a course. Course approval information will also be available onsite in the Education Office.

SUNDAYAPRIL3

		CLINICAL			CONTACT LENS
7:15AM -	41C1			41C4	
8:15AM	Clinical Ocular Grand Rounds Lonsberry This course is 2 hours from 7:15am - 9:15am			Florida Prevention of Medical Errors Sowka This course is 2 hours from 7:15am - 9:15am	
8:30AM -		42C2	42C3		42L1
9:30AM		CSI: Anterior Segment Case Files Whitley, Koetting This course is 2 hours from 8:30am -10:30am	Red Eyes – It's Just Conjunctivitis or Is It? Johnston		Contact Lens Management of Keratoconus Quinn, Bennett This course is 2 hours from 8:30am - 10:30am
	C, FL-OD				
	484		C,FL-OD, TPA	C, FL-OD	
9:45AM – 10:45AM	A New Era in Cataract and Refractive Surgical Management Johnston		Treatment and Management of Glaucoma Lonsberry This course is 2 hours from 9:45am - 11:45am	Florida Jurisprudence Sowka This course is 2 hours from 9:45am - 11:45am	
	C, FL-OD	C, FL-OD			C,FL-OD,N-O2
11:00AM - 12:00PM		44C2 Urgency vs. Emergency Koetting			
		C,FL-OD	C, FL-OD	C, FL-OD	
12:15PM – 1:15PM					

TRACK KEY

Anterior Segment	Glaucoma	Imaging Technology	Myopia
Non-Track	Optometric/Surgical Procedures	Pharmacology	Posterior Segment/Retina
Scleral Lens	Surgical/Co-Management	Systemic Disease/Diabetes	

OPTICAL TECHNOLOGY			BUSINESS SOLUTIONS		
4101	4102	4103	41B1	41B2	
Optical Boot Camp Zeitlin	Mastering Prism Walker This course is 2 hours from 7:15am – 9:15am	Ten Clinical Pearls after the First 10,000 B.Russell	Attracting Quality Staff in a Full Employment Market Manso	The Lean Machine: A Systematic Approach to an Efficient and Cost Effective Practice Neufeld	
A-NO, NYS-D-B	A-O2	FL-T, N-O3, NYS-CL-I	A-NO	C,FL-OD	
4201		4203	42B1	42B2	
Eye Disease with Deadly Consequences Zeitlin		The Lost Art: GP Corneal Lens Fitting B. Russell	Maximize Revenue and Profits with Vision Care Plans Manso	Out With the Old, In With the New Helmus	
A-NO		FL-T, N-O2, NYS-CL-I	A-NO	C, FL-OD	
4301		4303	43B1	43B2	43B3
Ophthalmic Merchandising Goffinet		Contact Lens Management of Infants and Children B. Russell	Breaking Current Practice Barriers Manso	Creating Long Term Private Practice Success Through Real Estate Neufeld	Efficiently Planning for Practice Succession Cmejla
A-NO		FL-T, N-O3, NYS-CL-I	A-NO	C,FL-OD	C,FL-OD
4401		4403	44B1	44B2	44B3
Blue Light Parker		Anatomy of a Successful Optical Business Pierce	Spoil Your Clients in Luxury Eyewear Walker This course is 2 hours from 11:00am - 1:00pm	Demonstrating a Positive Attitude to Patients Manso This course is 2 hours from 11:00am - 1:00pm	Self-Care: Understanding the Importance of a Healthy (Financial) Mindset in Practice Ownership Cmejla
FL-T,NYS-D-I,A-O2		A-NO			C,FL-OD
			A-NO	A-NO	

EDUCATION REGISTRATION

- Course handouts will be available online prior to the Education Program. They will not be available onsite. After you register for your courses, you will be able to print your own course handouts and bring them to the Education Program. Course handouts will also be available online for one month after the program and on the Vision Expo Mobile App.
- In an effort to improve the Education registration process, badges will not be mailed. Please bring your confirmation letter with barcode onsite to Registration to have your badge and course itinerary printed when you arrive at the conference. This will ensure that you have the most up-to-date course information on your badge barcode and course itinerary, including room numbers.
- Your badge barcode will have all of your registered courses embedded in it, which is required for course entry. If you make any course changes onsite after you have already printed your badge, you will need to get a new badge printed so that your current courses are embedded in your updated badge barcode.
- After the Education Program, you will receive a letter via e-mail verifying your course attendance. Please submit this letter to your state board/national accreditation agency for license renewal. If you did not supply an e-mail address when you registered, please update your registration record by calling Client Services at 1.800.811.7151.

Prism is

Niche

Unnecessary

Not Worth It

Problematic

Complicated

Difficult-

Avoidable-

A Specialty

Poison

The Future

Become A Provider



Meet your newest irreplaceable team member!

Fully automated wavefront lens analyzer

The VX40 is fully automated and gives you everything you need with the push of a button in 30 seconds. Featured on Review of Optometric Business, the article "How to Sell Near-Task-Specific Glasses & Generate \$160,000+ Annually" explores the opportunity to expand profitability by selling Near-Task-Specific Lenses. The VX40 reads all lenses, including bifocals, progressives, freeform, and single vision lenses. It is compatible with virtually every lens technology and brand.

Visit us at booth #F4133 to experience a live demo of the VX40 and the rest of our integrated portfolio!

We are the global manufacturer and exclusive sales, service and training provider for Optovue, Visionix, Briot and Weco brands in North America. You can read about these emerging technologies, and more on our Digital Catalog. Scan QR code.







1 (800) 729-1959 Iuneautechusa.com/visionexpo



Brought to you by **REGENERON**

PUT YOUR PATIENTS WITH DIABETIC RETINOPATHY (DR)
ON THE PATH TOWARD
MANAGING THEIR DISEASE AND

SET THE COURSE FOR SUCCESS IN DR

DIABETIC RETINOPATHY: A GROWING PROBLEM THAT YOU CAN HELP MANAGE¹⁻⁴

Through early detection, monitoring, and timely referral, you play a pivotal role in managing your DR patients' vision²⁻⁴

If you see or suspect DR:



Educate your patients about the severity of DR, especially when left untreated^{3,4}

• Your early and frequent discussions about disease progression, treatment options, and referral will empower patients, which could help them avoid significant vision loss^{3,4}



According to the AOA, you should refer patients with³:

- Severe nonproliferative DR (NPDR) within 2 to 4 weeks
- Proliferative DR (PDR) within 2 to 4 weeks
- High-risk PDR with or without macular edema within 24 to 48 hours



Ensure patients have followed up with a retina specialist who can treat DR



Monitor your patients with DR^{3,4}

The AOA recommends frequent monitoring of patients³

 At least every 6 to 8 months in patients with moderate NPDR and more frequently for patients with greater disease severity³



Refer patients to a specialist who can treat DR^{3,4}

Regeneron is committed to helping you partner with your patients for comprehensive care of DR, as well as for care of other retinal diseases.

AOA = American Optometric Association

References: 1. Diabetic Retinopathy. Centers for Disease Control and Prevention website. http://bit.ly/2BKTVCTS. Accessed January 17, 2020. 2. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 suppl):823-833. 3. Care of the Patient With Diabetes Mellitus: Quick Reference Guide. American Optometric Association website. http://bit.ly/2M22OUJ. Accessed January 17, 2020. 4. Ferrucci S, Yeh B. Diabetic retinopathy by the numbers. Rev Optom. June 15, 2016. http://bit.ly/2KNNJ4E. Accessed January 17, 2020.



Experience a complete suite of advanced visual health solutions

We are the global manufacturer and exclusive sales, service and training provider for Optovue®, Visionix®, Briot® and Weco® brands in North America.

We are the pioneer in integrating core refractive, screening, and imaging technologies to address the needs of eye care professionals in this dynamic market. Today, we are proud to offer high-speed OCT and OCTA technology designed to facilitate diagnosing and managing a range of ocular diseases.

Our goal is to improve access to forward-thinking technology that transforms the patient experience. With over 100 years of innovation, an expanded product line, as well as a new level of support, clinical education, and practice integration, we are well-positioned to help you unlock your potential

The latest in OCT and OCTA

Avanti Widefield OCT offers state-of-the-art imaging from the cornea to the choroid with exclusive technology that will change your approach to disease diagnosis and management. When you're ready, add AngioVue OCT Angiography (OCTA) to the Avanti platform to bring non-invasive vascular imaging with measurement tools to your practice. Ease into OCTA with AngioVue Essential or choose AngioVue Comprehensive to access all available OCTA features. For the retina specialist, there's AngioVue Retina, retina-only OCT and OCTA.



Unrivaled control of lens quality

Briot® Couture is a highly intuitive finishing solution for any Optical. Inspired by our popular Briot® Attitude edger, Couture is the world's first finishing platform that is powered by innovative virtual 3D rendering technology, allowing Opticians to visualize the final output before edging.

New technologies to thrive in the next normal

The Visionix product line combines multiple test functionalities in a small package—providing all necessary data for a comprehensive exam with significantly less patient movement from instrument to instrument. The compact Eye Refract and VX650 can be placed on a single tabletop or set up separately in a five square feet pre-test room. The optional table's ergonomic design even allows a wheelchair to fit comfortably, an excellent benefit for practitioners who see patients with special needs.



The second-generation Eye Refract is a highly automated and dynamic wavefront-based phoropter that includes a digital acuity short chart and the VX40 lens analyzer. The new VX650 combines a 45-degree fundus camera with advanced objective refraction, topography, wavefront aberrometry, tomography, and more.

New product releases to be revealed at booth #F4133! Experience it yourself at Vision Expo East.



You can read about these emerging technologies, and more on our Digital Catalog. Scan QR code.

1 (800) 729-1959 Iuneautechusa.com/visionexpo



For additional safety information about Xiidra®, please refer to the brief summary of Prescribing Information below.

*Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in DED is not known.¹⁻³

References: 1. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020. 2. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II Pathophysiology Report. Ocul Surf. 2017;15(3):438-510. 3. Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33(1):5-12.

XIIDRA, the XIIDRA logo and ii are registered trademarks of Novartis AG.

XIIDRA® (lifitegrast ophthalmic solution), for topical ophthalmic use Initial U.S. Approval: 2016

BRIEF SUMMARY: Please see package insert for full prescribing information.

1 INDICATIONS AND USAGE

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

4 CONTRAINDICATIONS

Xiidra® is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation [see Adverse Reactions (6.2)].

6 ADVERSE REACTIONS

• Hypersensitivity [see Contraindications (4)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In five clinical studies of DED conducted with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received lifitegrast 5%). The majority of patients (84%) had ≤ 3 months of treatment exposure. One hundred-seventy patients were exposed to lifitegrast for approximately 12 months. The majority of the treated patients were female (77%). The most common adverse reactions reported in 5%-25% of patients were instillation-site irritation, dysgeusia, and reduced visual acuity.

Other adverse reactions reported in 1%-5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, and sinusitis.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Xiidra. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Rare cases of hypersensitivity, including anaphylactic reaction, bronchospasm, respiratory distress, pharyngeal edema, swollen tongue, and urticaria have been reported. Eye swelling and rash have been reported [see Contraindications (4)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on Xiidra use in pregnant women to inform any drug-associated risks. Intravenous (IV) administration of lifitegrast to pregnant rats, from pre-mating through gestation Day 17, did not produce teratogenicity at clinically relevant

systemic exposures. Intravenous administration of lifitegrast to pregnant rabbits during organogenesis produced an increased incidence of omphalocele at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the recommended human ophthalmic dose [RHOD], based on the area under the curve [AUC] level). Since human systemic exposure to lifitegrast following ocular administration of Xiidra at the RHOD is low, the applicability of animal findings to the risk of Xiidra use in humans during pregnancy is unclear [see Clinical Pharmacology (12.3) in the full prescribing information].

<u>Data</u>

Animal Da

Lifitegrast administered daily by IV injection to rats, from pre-mating through gestation Day 17, caused an increase in mean pre-implantation loss and an increased incidence of several minor skeletal anomalies at 30 mg/kg/day, representing five, 400-fold the human plasma exposure at the RHOD of Xiidra, based on AUC. No teratogenicity was observed in the rat at 10 mg/kg/day (460-fold the human plasma exposure at the RHOD, based on AUC). In the rabbit, an increased incidence of omphalocele was observed at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the RHOD, based on AUC), when administered by IV injection daily from gestation Days 7 through 19. A fetal no observed adverse effect level (NOAEL) was not identified in the rabbit.

8.2 Lactation

Risk Summary

There are no data on the presence of lifitegrast in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to lifitegrast from ocular administration is low [see Clinical Pharmacology (12.3) in the full prescribing information]. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for Xiidra and any potential adverse effects on the breastfed child from Xiidra.

8.4 Pediatric Use

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Manufactured for: Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936 T2019-110



Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936-1080

© 2021 Novartis 11/21 162927



iCare **EIDON**

Eidon Ultra-Widefield: Now covering 200 degrees

iCare's unique combination of sharpness and TrueColor offers now even wider view on the retina from 120 with a single shot, up to 200 with Mosaic functionality, helping to detect subtle signs of pathologies further in the periphery.*

- + Ultra-Widefield of view up to 200°
- + Rich in details from center to periphery
- + Imaging through media opacities
- * Ultra-Widefield imaging is available with the optional **EIDON UWF Module**



iCare IC200

200 degrees of tonometry

- + Supine, recline & seated operations
- + No corneal disruptions
- + Suitable for every patient
- + Single use probes to exceed infection control guidelines



For more information, scan, call 888.422.7313, or email infoUSA@icare-world.com

For better perception ICare

Using Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL system, the iLink corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1



GET THERE IN TIME

When you see patients with signs of keratoconus, don't hesitate. Refer them for iLink[™]— the only FDA-approved cross-linking procedure that slows or halts disease progression and is eligible for commercial insurance coverage with over 95% of commercially covered lives.

Connect with an iLink[™] **expert today.** Visit iLinkExpert.com

Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5'-phosphate ophthalmic solution) are indicated for use with the KXL system in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking should not be performed on pregnant women.

IMPORTANT SAFETY INFORMATION

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

non ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision

These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa" Viscous and Photrexa" are manufactured for Avedro. The KXL" system is manufactured by Avedro. Avedro is a Glaukos of

REFERENCE: 1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc; 2016.

MA-02164A PM-US-0427

iLink is a trademark of Glaukos Corporation, Photrexa Photrexa Viscous, and the KXL system are registered trademarks of Avedro, a Glaukos company, All rights reserved, ©202

Transforming Patient Care, Together

Your partner for diagnosis, management, and workflow













Every solution ZEISS creates must satisfy two high standards. It must deliver quality that improves patient care, and it must reward the practitioner's investment. At ZEISS, we have one commitment: be the best at our jobs so you can be the best at yours.

ZEISS partners with you to understand your challenges from the inside. We design all of our products specifically for you, the medical professional. Our solutions are integrated from the start to improve efficiency and precision. The end result is better workflow and better patient care.

Join ZEISS at Vision Series Lunch Symposium¹:

Glaucoma Management: The Value of Enhancing the Patient Experience April 2nd

12:15 PM - 1:15 PM EDT




Seeing beyond

Experience the Heru platform for yourself in **Booth P1535**

No eye left behind

Perform a visual field in 20 seconds with Heru's Fast Pattern exam.



Screen Every Patient.

Detect Disease Early.

Enhance Patient Care.





¹ In accordance with Open Payments ("Sunshine") provisions of the Patient Protection and Affordable Care Act (and similar state laws), the value of the food and beverage is subject to public disclosure, and therefore will be reported in compliance with all applicable laws. State of Vermont HCPs: This event was organized and paid for by Carl Zeiss Meditec, Inc. Partaking of the food and beverages is prohibited under Vermont's 'Gift Ban'.

VISION 2022 EXPONYC

MARCH 31 - APRIL 3 | JAVITS CENTER | NYC

©VISIONEXPO

REGISTRATION IS NOW OFFICIALLY OPEN!

VEE2022.com/Register